{
  "url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-order-2000/article-3",
  "json_url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-order-2000/article-3.json",
  "legislation": "uksi/2000/1917",
  "legislation_title": "The Prescription Only Medicines (Human Use) Amendment Order 2000",
  "legislation_url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-order-2000",
  "path": "article/3",
  "kind": "article",
  "number": "3",
  "heading": "Amendment of Schedule 1 to the principal Order concerning specified substances and exemptions from the restrictions on sale and supply",
  "text": "In Schedule 1 to the principal Order (which specifies substances which, if included in medicinal products, make those products prescription only medicines, and exemptions from the restrictions on sale and supply of prescription only medicines)—\n(a) in relation to the substance Ibuprofen, there are inserted the following entries—\nin column 2—\n“(3) 10.0 per cent”,\nin column 3—\n“(3) External”,\nin column 4—\n“(3) 125 mg (MD) 500 mg (MDD)”, and\nin column 5—\n“(3) Container or package containing not more than 100 g of medicinal product”;\n(b) there is inserted in column 1, at the appropriate place in the alphabetical order of the entries as they appear in that column, the entry set out in column 1 below, and, against that entry there is inserted in columns 2, 3 and 5 the corresponding entries in columns 2, 3 and 5 below—\nColumn 1\nColumn 2\nColumn 3\nColumn 5\nSubstance\nMaximum strength\nUse, pharmaceutical form or route of administration\nMaximum quantity\nTerbinafine Hydrochloride\n1.0 per cent\nExternal use for the treatment of tinea pedis and tinea cruris\nContainer or package containing not more than 15 g of medicinal product.\n; and\n(c) there is inserted in column 1, at the appropriate place in the alphabetical order of the entries as they appear in that column, each of the following substances—\n“Acamprosate”\n“Aceclofenac”\n“Alendronate Sodium”\n“Anastrozole”\n“Didanosine”\n“Eformoterol Fumarate”\n“Imidapril Hydrochloride”\n“Mirtazapine”\n“Moxonidine”\n“Omeprazole Magnesium”\n“Ranitidine Bismuth Citrate”\n“Rimexolone”\n“Sertraline Hydrochloride”\n“Sevoflurane”\n“Tazarotene”\n“Topiramate”.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2000/1917/article/3",
    "retrieved_at": "2026-10-29T09:05:52.734681+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}